Successful Aortic Aneurysm Repair in a Woman with Severe von Willebrand (Type 3) Disease

Table 2

VWF:FVIII concentrates validated in clinical studies involving relatively large number of VWD patients.

Concentrate	Manufacturer	VWF:RCo/FVIII	Viral inactivation	Purification methodology
Alphanate [15]	Grifols (USA)	1.2	Solvent detergent, dry heat	Heparin ligand chromatography,
Biostate [17, 31, 32]	CSL Behring	2.0	Solvent detergent, dry heat	precipitation, and heparin ligand chromatography
Fanhdi [15, 33]	Grifols (SP)	1.6	Solvent detergent, dry heat	Precipitation, heparin ligand chromatography
Haemate-P (Humate-P) [16, 19, 20, 26, 27]	CSL Behring	2.5	Pasteurization	Polyelectrolyte precipitation
Wilate [34]	Octapharma	0.8	Solvent detergent, dry heat	Affinity chromatography, size exclusion
Wilfactin [18, 35]	LFB (Lille)	60	Solvent detergent, nanofiltration, and dry heat	Ion-exchange, affinity chromatography

Ratio of ristocetin cofactor activity (VWF:RCo) to FVIII activity expressed as IU/mL.